中国非瓣膜性房颤患者利伐沙班群体药代动力学研究
该前瞻性多中心研究在中国非瓣膜性房颤患者中建立利伐沙班群体药代动力学模型,纳入150例患者,最终模型显示表观清除率5.79 L/h、表观分布容积51.5 L,协变量包括肌酐清除率、总胆红素、rs4728709和体重。模拟提示15 mg每日一次可能适合作为中国患者的主要剂量,rs4728709突变者可能需关注抗凝不足。
要点
- 中国NVAF患者利伐沙班群体药代动力学模型提示15 mg每日一次可能为主要适宜剂量。
- ABCB1 rs4728709突变者在10、15、20 mg每日一次方案下稳态谷浓度低于目标范围。
- 利伐沙班校准抗Xa测定与HPLC-MS/MS法高度线性相关(R2=0.97)。
核心结论
- 本研究首次建立中国NVAF患者利伐沙班多中心群体药代动力学模型(Alfalfa-RIVAAF-PPK)。
- 15 mg每日一次可能适合作为中国NVAF患者利伐沙班的主要剂量。
- rs4728709突变患者可能需检查抗凝是否不足。
研究设计与样本
- 前瞻性多中心研究,共纳入5个中心的150例NVAF患者。
- 采用HPLC-MS/MS检测263份血浆浓度,抗Xa测定检测131份血浆浓度,并检测2626个基因多态性。
- 采用非线性混合效应模型建立群体药代动力学模型,并模拟不同剂量策略下的稳态暴露。
主要发现
- 口服一室模型描述利伐沙班药代动力学,最终模型表观清除率5.79 L/h(RSE 4.4%),表观分布容积51.5 L(RSE 5.0%)。
- 最终模型协变量包括肌酐清除率、总胆红素、rs4728709和体重。
- 15 mg每日一次方案下,多数情况下不同协变量水平的稳态峰浓度和谷浓度在目标范围内。
- 15或20 mg每日一次时,不同体重水平的稳态峰浓度和谷浓度也在目标范围内。
- rs4728709突变者在10、15、20 mg每日一次方案下稳态谷浓度低于目标范围。
关键数值与推荐
- 最终模型表观清除率5.79 L/h(RSE 4.4%),表观分布容积51.5 L(RSE 5.0%)。
- 15 mg每日一次方案下多数情况稳态峰浓度和谷浓度在目标范围内。
- rs4728709突变者10、15、20 mg每日一次方案下稳态谷浓度低于目标范围。
- 抗Xa测定与HPLC-MS/MS法线性相关:y=1.014x-2.4648(R2=0.97)。
临床怎么用
- 中国NVAF患者可考虑15 mg每日一次作为利伐沙班主要剂量。
- 对携带ABCB1 rs4728709突变者,应关注抗凝不足风险。
- 利伐沙班校准抗Xa测定与HPLC-MS/MS法高度相关,可作为浓度监测的替代方法。
局限性
- 需要更大样本的前瞻性研究和真实世界研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Rivaroxaban is a novel oral anticoagulant widely used for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF). The present study aimed to develop a population pharmacokinetic (PPK) model for rivaroxaban in Chinese patients with NVAF. METHODS: We performed a prospective multicenter study. The plasma concentration of rivaroxaban was directly detected by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and indirectly by rivaroxaban-calibrated chromogenic anti-Xa assay (STA®). Gene polymorphisms were detected by MassARRAY single nucleotide polymorphism genotyping technology. Nonlinear mixed-effects modeling was used to develop the PPK model for rivaroxaban in patients with NVAF, and we simulated the steady-state rivaroxaban exposures under different dosing strategies in different covariate levels. RESULTS: A total of 150 patients from five centers were recruited, including 263 plasma concentrations detected by HPLC-MS/MS, 2626 gene polymorphisms, and 131 plasma concentrations detected by anti-Xa assay. In our study, an oral one-compartment model was used to describe the pharmacokinetics of rivaroxaban in patients with NVAF. In the final model, the estimated apparent clearance (CL/F) and volume of distribution (V/F) were 5.79 L/h (relative standard error [RSE] 4.4%) and 51.5 L (RSE 5.0%), respectively. Covariates in the final model included creatinine clearance, total bilirubin, rs4728709, and body weight. The simulation results showed that in the 15 mg once-daily dosing regimen, in most instances the maximum plasma concentration at steady state (Cmax,ss) and trough plasma concentration at steady state (Cmin,ss) were in the target range for different covariate levels. When patients were administered rivaroxaban 15 or 20 mg once daily, the Cmax,ss and Cmin,ss in the different bodyweight levels were also in the target range. For patients with the ABCB1 rs4728709 mutation, the Cmin,ss in the 10, 15, and 20 mg once-daily dosing regimens were lower than the target range. The anti-Xa assay was highly linearly correlated with the HPLC-MS/MS method [y = 1.014x - 2.4648 (R2 = 0.97)]. CONCLUSIONS: Our study was the first multicenter PPK model for rivaroxaban in Chinese patients with NVAF (Alfalfa-RIVAAF-PPK). The study found that 15 mg once daily may be suitable as the principal rivaroxaban dose for Chinese patients with NVAF. For patients with the rs4728709 mutation, it may be necessary to examine insufficient anticoagulation. We found that the rivaroxaban-calibrated chromogenic anti-Xa assay and HPLC-MS/MS method were highly linearly correlated. Prospective studies with larger sample sizes and real-world studies are needed for further verification.
引用
- Zhang F, Chen X, Wu T, et al. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study. Clin Pharmacokinet. 2022. PMID: 35316848. doi:10.1007/s40262-022-01108-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。